Tenaya Therapeutics, Inc. Common Stock
TNYA Real Time Price USDRecent trades of TNYA by members of U.S. Congress
|
Name
|
Type
|
Shares
|
Price
|
Shares Held
|
Date
|
Reported
|
|---|
|
Investor
|
Shares
|
Change in Shares
|
Market Value
|
Date
|
Reported
|
|---|
|
Investor
|
Type
|
Shares
|
Change in Shares
|
Market Value
|
Date
|
Reported
|
|---|
Recently reported changes in TNYA holdings by institutional investors
Quarterly net insider trading by TNYA's directors and management
* Insider trading data parsed from SEC Form 4 filings by Quiver Quantitative. Sign up for the Quiver API for real-time access.
- 1M
- 3M
- 6M
- YTD
- 1Y
- 2Y
- 5Y
- MAX
About
Key Metrics
Return (1d)
Return (30d)
Return (1Y)
CAGR (Total)
Max Drawdown
Beta
Alpha
Sharpe Ratio
Win Rate
Average Win
Average Loss
Annual Volatility
Annual Std Dev
Information Ratio
Treynor Ratio
Total Trades
Metrics Definitions
Disclaimer: The performance results shown are based on historical backtesting and are hypothetical in nature. Backtested performance does not represent actual trading and does not account for all market factors that may affect execution, such as liquidity, slippage, and changing market conditions. Past performance is not necessarily indicative of future results. There is no guarantee that any trading strategy will be profitable or avoid losses.
-
Alpha
Measures a portfolio's risk-adjusted performance against that of its benchmark
Learn More -
Annual Standard Deviation
Measures how much the portfolio's total return varies from its mean or average.
Learn More -
Annual Volatility
A statistical measure of the dispersion of returns for the portfolio.
Learn More -
Average Win
The average return (%) for trades that resulted in a positive return.
-
Average Loss
The average return (%) for trades that resulted in a negative return.
-
Beta
A measure of the volatility of the portfolio compared to the market as a whole.
Learn More -
CAGR
CAGR (Compounded Annual Growth Rate), is the historical annualized rate of return for an investment strategy, throughout the backtest period.
Learn More -
Information Ratio
A measurement of portfolio returns beyond the returns of its benchmark compared to the volatility of those returns.
Learn More -
Max Drawdown
the maximum observed loss from a peak to a trough of a portfolio, before a new peak is attained.
Learn More -
Sharpe Ratio
The Sharpe Ratio is a measure of historical risk-adjusted return, which quantifies the amount of return that an investor received per unit of risk.
Learn More -
Total Trades
The total number of trades made by this strategy.
-
Treynor Ratio
Attempts to measure how successful an investment is in providing compensation to investors for taking on investment risk.
Learn More -
Win Rate
The percentage of total trades that resulted in a positive return.
Be the first to see our newest insights and key updates across all datasets.
Government lobbying spending instances
TNYA Estimated quarterly lobbying spending
TNYA Revenue by Segment or Geography
New TNYA patent grants
-
Patent Title: Gene therapy vectors for treating heart disease Nov. 25, 2025
-
Patent Title: Fluoroalkyl-oxadiazoles and uses thereof May. 27, 2025
-
Patent Title: Hdac6 inhibitors for treatment of metabolic disease and hfpef Jan. 21, 2025
-
Patent Title: Cardiac cell reprogramming with myocardin and ascl1 Dec. 17, 2024
-
Patent Title: Optimized expression cassettes for gene therapy Nov. 26, 2024
-
Patent Title: Adeno-associated virus with engineered capsid Oct. 01, 2024
-
Patent Title: Fluoroalkyl-oxadiazoles and uses thereof Mar. 12, 2024
-
Patent Title: Cardiac cell reprogramming with myocardin and ascl1 Feb. 27, 2024
-
Patent Title: Plakophillin-2 gene therapy methods and compositions Oct. 10, 2023
-
Patent Title: Gene therapy vectors for treating heart disease Sep. 19, 2023
-
Patent Title: Fluoroalkyl-oxadiazoles and uses thereof Feb. 14, 2023
-
Patent Title: Gene therapy vectors for treating heart disease Sep. 20, 2022
-
Patent Title: Gene therapy vectors for treating heart disease Sep. 28, 2021
-
Patent Title: Cardiac cell reprogramming with myocardin and ascl1 May. 25, 2021
Federal grants, loans, and purchases
Estimated quarterly amount awarded to TNYA from public contracts
Recent insights relating to TNYA
Recent picks made for TNYA stock on CNBC
ETFs with the largest estimated holdings in TNYA
- ... Highest Price Target
- ... Median Price Target
- ... Lowest Price Target
|
Analyst
|
Firm
|
Current
|
Previous
|
Date
|
|---|
- Is $TNYA stock a Buy, Sell, or Hold?
- What is the price target for $TNYA stock?
* Analyst consensus is not financial advice. Please see our data disclaimers .
|
Shareholder
|
Shares Held
|
|---|
- Who owns $TNYA stock?
- Who owns the most shares of $TNYA stock?
- What funds own $TNYA stock?
* These are estimates based on data taken from SEC filings. There may be inaccuracies due to parsing errors, accidental double-counting, incorrect classification of indirectly owned shares, or any other number of issues.
The Quiver Smart Score combines our data on Congress Trading, Lobbying, Insider Trading, CNBC Mentions and more to provide a comprehensive view of the strength of a stock's underlying data.
The Smart Score grades stocks on a scale of 1 (weakest) to 10 (strongest) based on the strength of the underlying data.Sign Up to view TNYA Smart Score
See concise summaries of analyst reports, presenting both bullish and bearish arguments for a stock.
Example:
The Bulls Say summary highlights positive aspects of the stock.
The Bears Say summary points out potential risks and negative aspects of the stock.
Tenaya Therapeutics Inc is a preclinical stage biotechnology company focused on discovering, developing, and delivering curative therapies that address the underlying drivers of heart disease. It is advancing product candidates from three product platforms: gene therapy, cellular regeneration and precision medicine.
- Address South San Francisco, CA
- Market Cap 234.8 million
- Employees 97
- Industrial Classification Biological Products, (No Disgnostic Substances)